HRP20100064T1 - Postupci za poboljšanje bioraspoloživosti inhibitora renina - Google Patents

Postupci za poboljšanje bioraspoloživosti inhibitora renina Download PDF

Info

Publication number
HRP20100064T1
HRP20100064T1 HR20100064T HRP20100064T HRP20100064T1 HR P20100064 T1 HRP20100064 T1 HR P20100064T1 HR 20100064 T HR20100064 T HR 20100064T HR P20100064 T HRP20100064 T HR P20100064T HR P20100064 T1 HRP20100064 T1 HR P20100064T1
Authority
HR
Croatia
Prior art keywords
hydroxy
amino
inhibitor
aryl
alkanoic acid
Prior art date
Application number
HR20100064T
Other languages
English (en)
Croatian (hr)
Inventor
P. Camenisch Gian
Gross Gerhard
Ottinger Isabel
Wasmuth Daniel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100064(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20100064T1 publication Critical patent/HRP20100064T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20100064T 2004-08-03 2005-08-02 Postupci za poboljšanje bioraspoloživosti inhibitora renina HRP20100064T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03
PCT/EP2005/008369 WO2006013094A1 (fr) 2004-08-03 2005-08-02 Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine

Publications (1)

Publication Number Publication Date
HRP20100064T1 true HRP20100064T1 (hr) 2010-03-31

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100064T HRP20100064T1 (hr) 2004-08-03 2005-08-02 Postupci za poboljšanje bioraspoloživosti inhibitora renina

Country Status (31)

Country Link
US (1) US7709532B2 (fr)
EP (2) EP1776099B1 (fr)
JP (1) JP5134366B2 (fr)
KR (1) KR20070040384A (fr)
CN (1) CN1993116B (fr)
AR (1) AR050043A1 (fr)
AT (1) ATE449601T1 (fr)
AU (1) AU2005268844B2 (fr)
BR (1) BRPI0514021A (fr)
CA (1) CA2572743C (fr)
CY (1) CY1109826T1 (fr)
DE (1) DE602005017905D1 (fr)
DK (1) DK1776099T3 (fr)
EC (1) ECSP077169A (fr)
ES (1) ES2335597T3 (fr)
HR (1) HRP20100064T1 (fr)
IL (1) IL180678A (fr)
MA (1) MA28821B1 (fr)
MX (1) MX2007001339A (fr)
MY (1) MY142180A (fr)
NO (1) NO20071142L (fr)
NZ (1) NZ552903A (fr)
PE (1) PE20060416A1 (fr)
PL (1) PL1776099T3 (fr)
PT (1) PT1776099E (fr)
RU (1) RU2404758C2 (fr)
SI (1) SI1776099T1 (fr)
TN (1) TNSN07038A1 (fr)
TW (1) TW200616610A (fr)
WO (1) WO2006013094A1 (fr)
ZA (1) ZA200610639B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (fr) * 2006-08-25 2008-02-27 Novartis AG Formulations galéniques de l'aliskiren
EP1927350A1 (fr) * 2006-11-24 2008-06-04 Novartis AG Procéde pour améliorer la biodisponibilite d'un inhibiteur de renine
CA2769392A1 (fr) 2009-07-31 2011-02-03 Sandoz Ag Procede de preparation de ?o-amino-alcaneamides et o-amino-alcanethioamides
WO2012010651A2 (fr) 2010-07-23 2012-01-26 Sandoz Ag Procédé de préparation d'oméga-amino-alcaneamides et d'oméga-amino-alcanethioamides et intermédiaires de ce procédé
JP6385340B2 (ja) * 2013-04-12 2018-09-05 国立大学法人京都大学 巨核球の成熟化促進物質
US10201552B2 (en) 2013-09-05 2019-02-12 Howard University Method of increasing the bioavailability of an HIV drug
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (fr) 1995-06-07 1996-12-19 Avmax, Inc. Utilisation d'huiles essentielles pour accroitre la biodisponibilite des composes pharmaceutiques oraux
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE69808303T2 (de) * 1997-08-14 2003-05-22 Aventis Pharmaceuticals Inc., Bridgewater Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
CA2398567A1 (fr) * 2000-02-11 2001-08-16 Praecis Pharmaceuticals Incorporated Procedes permettant d'ameliorer la biodisponibilite d'un medicament
WO2001092468A2 (fr) 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Nouvelles compositions pour l'expression du transporteur 1 d'histidine de peptide humain et leurs procedes d'utilisation
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
EP1465592A2 (fr) 2001-12-19 2004-10-13 Alza Corporation Preparation et forme posologique pour l'augmentation de la biodisponibilite buccale de macromolecules hydrophiles
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
WO2004002466A1 (fr) * 2002-06-28 2004-01-08 Speedel Pharma Ag Formulation pharmaceutique comprenant un inhibiteur de renine non peptidique et un tensioactif
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders

Also Published As

Publication number Publication date
PL1776099T3 (pl) 2010-05-31
CY1109826T1 (el) 2014-09-10
RU2404758C2 (ru) 2010-11-27
DK1776099T3 (da) 2010-03-01
CA2572743C (fr) 2012-12-04
BRPI0514021A (pt) 2008-05-27
CA2572743A1 (fr) 2006-02-09
PT1776099E (pt) 2010-01-06
KR20070040384A (ko) 2007-04-16
DE602005017905D1 (de) 2010-01-07
CN1993116B (zh) 2011-04-13
MY142180A (en) 2010-10-15
SI1776099T1 (sl) 2010-03-31
EP1776099B1 (fr) 2009-11-25
AR050043A1 (es) 2006-09-20
JP5134366B2 (ja) 2013-01-30
TNSN07038A1 (en) 2008-06-02
JP2008508340A (ja) 2008-03-21
US7709532B2 (en) 2010-05-04
EP2191823A1 (fr) 2010-06-02
NO20071142L (no) 2007-04-26
EP1776099A1 (fr) 2007-04-25
CN1993116A (zh) 2007-07-04
IL180678A (en) 2011-04-28
ZA200610639B (en) 2008-05-28
AU2005268844B2 (en) 2009-03-05
AU2005268844A1 (en) 2006-02-09
RU2007107850A (ru) 2008-09-10
IL180678A0 (en) 2008-03-20
NZ552903A (en) 2010-09-30
PE20060416A1 (es) 2006-06-09
ECSP077169A (es) 2007-02-28
TW200616610A (en) 2006-06-01
ATE449601T1 (de) 2009-12-15
US20080108703A1 (en) 2008-05-08
MA28821B1 (fr) 2007-08-01
ES2335597T3 (es) 2010-03-30
WO2006013094A1 (fr) 2006-02-09
MX2007001339A (es) 2007-03-27

Similar Documents

Publication Publication Date Title
HRP20120494T1 (hr) Derivati purina za uporabu kao agonista adenozin a2a receptora
HRP20161657T1 (hr) Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta
HRP20020182B1 (en) Benzamide formulation with histone deacetylase inhibitor activity
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
HRP20241643T1 (hr) Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
ATE374765T1 (de) Substituierte heterocyclische amide
MEP44308A (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
AR037460A1 (es) Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
HRP20130900T1 (hr) Derivat (aza)indola i njegova uporaba u medicinske svrhe
ATE326453T1 (de) Antithrombotische amide
HRP20120327T1 (hr) Supstituirani indolil alkil amino derivati kao novi inhibitori histonske deacetilaze
CZ304762B6 (cs) (R)-2-Arylpropionamidové sloučeniny, jejich použití pro výrobu léčiva, farmaceutický prostředek s jejich obsahem a způsob jejich přípravy
HRP20100064T1 (hr) Postupci za poboljšanje bioraspoloživosti inhibitora renina
BRPI0506622A (pt) éster biciclo derivado; um intermediário na produção do éster biciclo derivado; produto farmacêutico contendo um ingrediente ativo do éster biciclo derivado; inibidor dpp-iv contendo um ingrediente ativo do éster biciclo derivado; agente terapêutico para uma doença envolvendo dpp-iv contendo um ingrediente ativo do éster biciclo derivado, e agente terapêutico
NO20020771L (no) Peptidformulering med forlenget frigjöring
EA200900827A1 (ru) Фармацевтический состав, содержащий антагонист нейрокининов
CA2605771A1 (fr) Methodes de traitement de l'atherosclerose
YU34396A (sh) Farmaceutske smeše korisne za minimiziranje oštećenja kostiju
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
RU2015120074A (ru) Функционализированные производные 9-бром-камптотецина
RU2008107871A (ru) Применение ингибиторов hdac для лечения миеломы
HRP20020181B1 (hr) Farmaceutski pripravci koji sadrže derivat benzamida kao aktivan sastojak
ATE226934T1 (de) Ester und amide als pla2-inhibitoren
TW202330014A (zh) 含有胜肽化合物及界面活性劑之組成物